Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 26, Issue 27, p.4449-57 (2008)


2008, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Center-Authored Paper, Chemotherapy, Adjuvant, Clinical Research Division, Cyclophosphamide, Disease-Free Survival, Doxorubicin, Female, Fluorouracil, Follow-Up Studies, Humans, Lymph Node Excision, Lymphatic Metastasis, Mastectomy, Middle Aged, Multivariate Analysis, Neoplasm Recurrence, Local, Positron-Emission Tomography, Premedication, Research Trials Office Core Facility - Biostatistics Service, Risk Assessment, Shared Resources, Survival Rate


Patients with locally advanced breast carcinoma (LABC) receive preoperative chemotherapy to provide early systemic treatment and assess in vivo tumor response. Serial positron emission tomography (PET) has been shown to predict pathologic response in this setting. We evaluated serial quantitative PET tumor blood flow (BF) and metabolism as in vivo measurements to predict patient outcome.